VOR News

Vor Bio Announces $150 Million Private Placement

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025